A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Hui Gan et al.|Annals of Oncology|2016Cited by 145
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Carla de Boer et al.|Blood|2016Cited by 110
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple MyelomaTorben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2014Cited by 49
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Torben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2015Cited by 40
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, David Goldstein|Journal for ImmunoTherapy of Cancer|2023Cited by 38